1
|
Meyers E, De Rop L, Engels F, Gioveni C, Coen A, De Burghgraeve T, Digregorio M, Van Ngoc P, De Clercq N, Buret L, Coenen S, Deschepper E, Padalko E, Callens S, Duysburgh E, De Sutter A, Scholtes B, Verbakel JY, Heytens S, Cools P. Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination. Vaccines (Basel) 2024; 12:951. [PMID: 39204074 PMCID: PMC11359559 DOI: 10.3390/vaccines12080951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 08/20/2024] [Accepted: 08/21/2024] [Indexed: 09/03/2024] Open
Abstract
When COVID-19 vaccines were implemented, nursing home residents (NHRs) and staff (NHS) in Belgium were prioritized for vaccination. To characterize the vaccine response over time in this population and to identify poorly responding groups, we assessed antibody concentrations two (T1), four (T2) and six months (T3) after primary course BNT162b2 vaccination in six groups of infection-naive/infection-primed NHRs/NHS, with/without comorbidity (NHRs only). Participant groups (N = 125 per group) were defined within a national serosurveillance study in nursing homes, based on questionnaire data. Dried blood spots were analyzed using ELISA for the quantification of SARS-CoV-2 S1RBD IgG antibodies. Among all groups, antibody concentrations significantly decreased between T1 and T2/T3, all with a ≥70% decrease at T3, except for infection-primed staff (-32%). Antibody concentrations among infection-naive NHRs were 11.96 times lower than those among infection-primed NHR, while the latter were comparable (x1.05) to infection-primed NHS. The largest proportion [13% (95% CI: 11-24%)] of vaccine non-responders was observed in the group of infection-naive NHRs with comorbidities. A longer interval between infection and vaccination (≥3 months) elicited higher antibody responses. Our data retrospectively show the necessity of timely COVID-19 booster vaccination. Infection-naive NHRs require special attention regarding immune monitoring in future epidemics or pandemics.
Collapse
Affiliation(s)
- Eline Meyers
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium; (E.M.); (F.E.)
| | - Liselore De Rop
- EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
| | - Fien Engels
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium; (E.M.); (F.E.)
| | - Claudia Gioveni
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium; (E.M.); (F.E.)
| | - Anja Coen
- Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium (S.H.)
| | - Tine De Burghgraeve
- EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
| | - Marina Digregorio
- Research Unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, 4000 Liège, Belgium
| | - Pauline Van Ngoc
- Research Unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, 4000 Liège, Belgium
| | - Nele De Clercq
- Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium (S.H.)
| | - Laëtitia Buret
- Research Unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, 4000 Liège, Belgium
| | - Samuel Coenen
- Department of Family Medicine & Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerp, Belgium
| | - Ellen Deschepper
- Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
| | - Elizaveta Padalko
- Laboratory of Medical Microbiology, Ghent University Hospital, 9000 Ghent, Belgium
| | - Steven Callens
- Department of Internal Medicine & Infectious Diseases, Ghent University Hospital, 9000 Ghent, Belgium
| | - Els Duysburgh
- Department of Epidemiology and Public Health, Sciensano, 1000 Brussels, Belgium
| | - An De Sutter
- Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium (S.H.)
| | - Beatrice Scholtes
- Research Unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, 4000 Liège, Belgium
| | - Jan Y. Verbakel
- EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
| | - Stefan Heytens
- Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium (S.H.)
| | - Piet Cools
- Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium; (E.M.); (F.E.)
| |
Collapse
|
2
|
Batmunkh B, Otgonbayar D, Shaarii S, Khaidav N, Shagdarsuren OE, Boldbaatar G, Danzan NE, Dashtseren M, Unurjargal T, Dashtseren I, Dagvasumberel M, Jagdagsuren D, Bayandorj O, Biziya B, Surenjid S, Togoo K, Bat-Erdene A, Narmandakh Z, Choijilsuren G, Batmunkh U, Soodoi C, Boldbaatar EA, Byambatsogt G, Byambaa O, Deleg Z, Enebish G, Chuluunbaatar B, Zulmunkh G, Tsolmon B, Gunchin B, Chimeddorj B, Dambadarjaa D, Sandag T. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia. PLoS One 2023; 18:e0295167. [PMID: 38064430 PMCID: PMC10707641 DOI: 10.1371/journal.pone.0295167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 11/16/2023] [Indexed: 12/18/2023] Open
Abstract
The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21-28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21-28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.
Collapse
Affiliation(s)
- Burenjargal Batmunkh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Dashpagma Otgonbayar
- National Center for Communicable Diseases of Mongolia, Ulaanbata, Mongolia
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Shatar Shaarii
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Nansalmaa Khaidav
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Oyu-Erdene Shagdarsuren
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gantuya Boldbaatar
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Nandin-Erdene Danzan
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | - Tsolmon Unurjargal
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ichinnorov Dashtseren
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | | | | | - Baasanjargal Biziya
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Seesregdorj Surenjid
- International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Khongorzul Togoo
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ariunzaya Bat-Erdene
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Zolmunkh Narmandakh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gansukh Choijilsuren
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ulziisaikhan Batmunkh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Chimidtseren Soodoi
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Enkh-Amar Boldbaatar
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ganbaatar Byambatsogt
- School of Nursing, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Otgonjargal Byambaa
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Zolzaya Deleg
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gerelmaa Enebish
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Bazardari Chuluunbaatar
- Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gereltsetseg Zulmunkh
- Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | - Batbaatar Gunchin
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Battogtokh Chimeddorj
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Davaalkham Dambadarjaa
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Tsogtsaikhan Sandag
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| |
Collapse
|
3
|
Inoue Y, Li Y, Yamamoto S, Fukunaga A, Ishiwari H, Ishii M, Miyo K, Ujiie M, Sugiura W, Ohmagari N, Mizoue T. The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study. Vaccine 2023; 41:7317-7321. [PMID: 37945490 DOI: 10.1016/j.vaccine.2023.10.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 09/05/2023] [Accepted: 10/13/2023] [Indexed: 11/12/2023]
Abstract
Antipyretic analgesics are used to manage and control symptoms occurring after vaccination, but may hamper immunogenicity or vaccine efficacy. We examined the association between prophylactic or therapeutic use of antipyretic analgesics and SARS-CoV-2 antibody titers for vaccine recipients. Data were obtained from 1,498 staff members of a medical and research institution in Tokyo, Japan, who had received the second dose of the BNT162b2 vaccine. We quantitatively measured anti-SARS-CoV-2 spike protein IgG titers in the participants three months after vaccination. The prophylactic and therapeutic use of antipyretic analgesics was ascertained via a questionnaire. A linear regression model was used to examine the association between antipyretic analgesic use and log-transformed anti-SARS-CoV-2 spike protein IgG titers. Based on model parameters, we estimated geometric mean titers (GMT) and the corresponding 95 % confidence intervals (CI). The results showed that IgG titers in vaccine recipients who used antipyretic analgesics therapeutically was higher than the titers in those who did not (geometric mean ratio [GMR] = 1.26, 95 % CI = 1.17-1.34) with GMTs being 6,147 (95 % CI = 5,833-6,460) and 4,895 (95 % CI = 4,676-5,115) for those who used antipyretic analgesics therapeutically and those who did not, respectively. The association was attenuated, but remained statistically significant after adjusting for symptoms (GMR = 1.14, 95 % CI = 1.06-1.23). We did not find any evidence of significant association in relation to the prophylactic use of antipyretic analgesics (GMR = 0.96, 95 % CI = 0.84-1.10), with GMTs being 5,245 (95 % CI = 4,577-5,913) and 5,452 (95 % CI = 5,258-5,645) for those who used antipyretic analgesics prophylactically and those who did not, respectively. In conclusion, we did not find any evidence of suppression of the humoral response after the second dose of SARS-CoV-2 vaccination by prophylactic or therapeutic use of antipyretic analgesics.
Collapse
Affiliation(s)
- Yosuke Inoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
| | - Yunfei Li
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Shohei Yamamoto
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Ami Fukunaga
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Hironori Ishiwari
- Center for Medical Informatics Intelligence, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Masamichi Ishii
- Center for Medical Informatics Intelligence, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Kengo Miyo
- Center for Medical Informatics Intelligence, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Mugen Ujiie
- Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Wataru Sugiura
- Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Mizoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| |
Collapse
|